[Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma]
- PMID: 19619443
[Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma]
Abstract
Background and objective: Clinical trials on docetaxel plus cisplatin (DDP) (TP regimen) in treating nasopharyngeal carcinoma (NPC) are still uncertain due to limited samples. This study was to compare the short-term efficacy and toxicity of induction chemotherapy with TP regimen followed by concurrent chemoradiotherapy with TP regimen versus DDP in treating locally advanced NPC.
Methods: Fifty-seven patients with stage T3-4N2-3M0 NPC diagnosed pathologically from December 2005 to December 2006 were randomized into TP group (30 patients) and DDP group (27 patients). Both groups received TP regimen as induction chemotherapy with docetaxel (70 mg/m(2)) on Day 1 and DDP (80 mg/m(2)) on Day 2, repeating every 21 days for 2 cycles. For concurrent chemotherapy, TP group were administered docetaxel (60 mg/m(2)) on Day 1 and DDP (80 mg/m(2)) on Day 2; DDP group were administered DDP (80 mg/m(2)) on Day 1. Both schedules were repeated every 21 days for 2 cycles. Linear accelerator was used as radioactive source. Irradiation field was designed with CT-simulation and conventional fractions.
Results: The 57 patients received 111 cycles of induction chemotherapy, and 53 of them received 103 cycles of concurrent chemotherapy; four patients ceased induction chemotherapy and three ceased concurrent chemotherapy. All patients completed radiotherapy. The major toxicity of induction chemotherapy was hematologic toxicity; the main toxicities of concurrent chemoradiotherapy were hematologic toxicity and mucositis. The occurrence rates of Grade 3-4 leucopenia and Grade 3-4 neutropenia were significantly higher in TP group than in DDP groups (p <0.05). In concurrent chemoradiotherapy, the application rate of granulocyte colony stimulating factor (G-CSF) was significantly higher in TP group than in DDP group (100% vs. 72.0%, p<0.05). After concurrent chemoradiotherapy, the complete remission (CR) rates of the nasopharynx and regional lymph nodes were 93.3% and 92.9% in TP group, and were 96.3% and 91.3% in DDP group (p>0.05).
Conclusions: The short-term efficacy of induction chemotherapy with TP regimen followed by concurrent chemoradiotherapy with TP regimen on locally advanced NPC is similar to that of TP regimen followed by concurrent chemoradiotherapy with DDP. The toxicity of the former schedule is severer than that of the latter, but it is tolerable with the use of G-CSF. The long-term efficacy of induction chemotherapy with TP regimen followed by concurrent chemoradiotherapy with TP regimen need to be further studied.
Similar articles
-
[Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].Zhonghua Zhong Liu Za Zhi. 2013 Aug;35(8):623-6. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 24314223 Clinical Trial. Chinese.
-
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].Ai Zheng. 2007 Aug;26(8):880-4. Ai Zheng. 2007. PMID: 17697552 Clinical Trial. Chinese.
-
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].Zhonghua Zhong Liu Za Zhi. 2015 Sep;37(9):676-81. Zhonghua Zhong Liu Za Zhi. 2015. PMID: 26813432 Clinical Trial. Chinese.
-
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.Oncologist. 2003;8(4):361-74. doi: 10.1634/theoncologist.8-4-361. Oncologist. 2003. PMID: 12897333 Review.
-
Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.Oncologist. 2021 Jan;26(1):e130-e141. doi: 10.1002/ONCO.13520. Epub 2020 Oct 1. Oncologist. 2021. PMID: 32924198 Free PMC article.
Cited by
-
Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study.Head Neck. 2025 Jan;47(1):263-268. doi: 10.1002/hed.27897. Epub 2024 Aug 11. Head Neck. 2025. PMID: 39129235 Free PMC article. Clinical Trial.
-
The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221109974. doi: 10.1177/15330338221109974. Technol Cancer Res Treat. 2022. PMID: 35770295 Free PMC article. Clinical Trial.
-
Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas.World J Clin Oncol. 2013 May 10;4(2):47-51. doi: 10.5306/wjco.v4.i2.47. World J Clin Oncol. 2013. PMID: 23696962 Free PMC article.
-
Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.J Cancer. 2021 Jan 1;12(1):18-27. doi: 10.7150/jca.49944. eCollection 2021. J Cancer. 2021. PMID: 33391399 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical